Gemcitabine + Cisplatin + Durvalumab + CTX-009
Phase 1/2Recruiting 0 watching 0 views this week💤 Quiet
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Biliary Tract Cancer
Conditions
Metastatic Biliary Tract Cancer
Trial Timeline
Jan 22, 2025 → May 1, 2029
NCT ID
NCT06548412About Gemcitabine + Cisplatin + Durvalumab + CTX-009
Gemcitabine + Cisplatin + Durvalumab + CTX-009 is a phase 1/2 stage product being developed by Compass Therapeutics for Metastatic Biliary Tract Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06548412. Target conditions include Metastatic Biliary Tract Cancer.
Hype Score Breakdown
Clinical
13
Activity
8
Company
5
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06548412 | Phase 1/2 | Recruiting |
Competing Products
20 competing products in Metastatic Biliary Tract Cancer